nivolumab与标准治疗三线小细胞肺癌的疗效比较。

PubMed ID
发表日期 2020年Dec月

原始出处 比较有效性研究杂志
Journal of comparative effectiveness research
作者 Keeping  Sam T  Cope  Shannon  Chan  Keith  Wilson  Florence R  Jansen  Jeroen P  Penrod  John R  Abraham  Pranav  Camidge  D Ross  Korytowsky  Beata  Gu  Tao  Garcia  Ariadna Juarez  Le  Trong K  Yuan  Yong 

文献标题 nivolumab与标准治疗三线小细胞肺癌的疗效比较。
Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer.

文献摘要

目的:评价nivolumab与标准治疗(SOC)在小细胞肺癌患者接受两种既往化疗(即美国第三种化疗)后总生存率(OS)方面的比较效果。材料与方法:数据来源于nivolumab单臂试验CheckMate 032,以及真实的电子病历。使用三种不同的方法进行OS的比较,以调整群体之间的差异(回归、加权和双稳健)。结果:在所有调整方法中,Nivolumab与SOC(OS危险比:0.58-0.70)相比,存活时间更长。结论:Nivolumab作为小细胞肺癌的第三线治疗方法,与美国目前的SOC相比,具有更高的疗效。


Aim: To estimate the comparative effectiveness of nivolumab versus standard of care (SOC) in terms of overall survival (OS) for small-cell lung cancer patients treated with two prior lines of chemotherapy, in other words, third line in the USA. Materials & methods: Data were from CheckMate 032, a single-arm trial of nivolumab, and real-world electronic patient records. Comparisons of OS were conducted using three different methods to adjust for differences (regression, weighting and doubly robust) between the populations. Results: Nivolumab was associated with longer survival compared with SOC (hazard ratio for OS: 0.58-0.70) across all methods for adjustment. Conclusion: Nivolumab was more efficacious in terms of OS as third-line treatment for small-cell lung cancer compared with current SOC in the USA.


获取全文 10.2217/cer-2020-0134